12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Company News  |  Deals

Genaissance, J&J deal

Under a non-exclusive license, GNSC will provide its haplotype (HAP) technology platform to JNJ's Janssen Research Foundation and R.W. Johnson Pharmaceutical Research Institute...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >